Marilyn J. Lemmon - Concepedia

Author

Marilyn J. Lemmon

Stanford University

Also Known As

M J Lemmon, M Lemmon, M. Lemmon, M.J. LEMMON, M.J. Lemmon, Marilyn J. Lemmon, Marilyn Lemmon, Monic E. Lemmon

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Stanford University Stanford Medicine SRI International

About

Marilyn J. Lemmon is an author at Stanford University specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	16	1.4K
2	Health Sciences	4	4	266
3	Natural Sciences	2	2	51
4	Biochemistry	2	2	408
5	Engineering	1	1	26

Marilyn J. Lemmon

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells Elaine M. Zeman, Jeremy Brown, Marilyn J. Lemmon, International Journal of Radiation OncologyBiologyPhysics High Selective ToxicityBiochemistryRedox RegulatorMedicineLipid Peroxidation	1986	393
Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents Leisa Johnson, Annie Shen, Larry Boyle, Cancer Cell Tumor BiologyImmunologyAntiviral ResponseSystemic Antitumor AgentsDeregulated E2f Activity	2002	190
Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Julia Brown, Marilyn J. Lemmon PubMed Fractionated IrradiationRadiation EffectCell DeathMouse TumorsRadiation Biology	1990	182
Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia. Mary E. Fox, Marilyn J. Lemmon, Margaret L. Mauchline, PubMed	1996	172
Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration. Carla Heise, Marilyn J. Lemmon, David H. Kirn PubMed PathologyTumor BiologyViral OncologyOvarian CancerCancer-associated Virus	2000	100
Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233 Elaine M. Zeman, V.Kate Hirst, Marilyn J. Lemmon, Radiotherapy and Oncology Tumor BiologyRadiation OncologyRadiation TherapyRadiation BiologyMedicine	1988	95
Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation Jeffrey M. Brown, Marilyn J. Lemmon International Journal of Radiation OncologyBiologyPhysics Tumor HypoxiaRadiation TherapyMedicineClinical Radiation OncologyOncology	1991	86
Mechanism of action of the selective tumor radiosensitizer nicotinamide Michael R. Horsman, J. Martin Brown, D. Phil, International Journal of Radiation OncologyBiologyPhysics Selective Tumor RadiosensitizerRadiation TherapyMedicineRadiopharmaceuticalsRadiopharmaceutical Therapy	1988	74
Structure-activity relationships for benzotriazine DI-N-oxides Elaine M. Zeman, Martha Baker, Marilyn J. Lemmon, International Journal of Radiation OncologyBiologyPhysics Organic ChemistryMolecular ChemistryStructure-activity RelationshipsChemistry	1989	64
Preferential tumor radiosensitization by analogs of nicotinamide and benzamide Michael R. Horsman, Dennis Brown, Marilyn J. Lemmon, International Journal of Radiation OncologyBiologyPhysics Radiation TherapyMedicineRadionuclide TherapyPharmacologyRadiopharmaceuticals	1986	46

Page 1